LC-MS characterization and purity assessment of a prototype bispecific antibody

mAbs

Volumn 5, Issue 5, 2013, Pages 711-722

  Jeremy Woods, R ^a   Xie, Michael Hongwei ^a   Kreudenstein, Thomas Spreter Von ^b   Ng, Gordon Y ^b   Dixit, Surjit B ^b  

^a KBI Biopharma Inc   (United States)

^b Zymeworks Inc   (Canada)

Author keywords

Bispecific antibody; Deglycosylation; Heterodimeric antibody; Impurity assessment; Intact protein mass; LC MS; Peptide map; Purity assay

Indexed keywords

BISPECIFIC ANTIBODY; BISPECIFIC IMMUNOGLOBULIN G ASYMMETRIC ANTIBODY; HOMODIMER; UNCLASSIFIED DRUG;

ARTICLE; DRUG PURITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BISPECIFIC ANTIBODY; DEGLYCOSYLATION; HETERODIMERIC ANTIBODY; IMPURITY ASSESSMENT; INTACT PROTEIN MASS; LC-MS; PEPTIDE MAP; PURITY ASSAY;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; CHROMATOGRAPHY, LIQUID; GLYCOSYLATION; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDE MAPPING; POLYSACCHARIDES; PROTEIN MULTIMERIZATION; REPRODUCIBILITY OF RESULTS;

EID: 84883869187     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.25488     Document Type: Article

References (21)

1. Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
2. Holmes D. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
3. Müller D, Kontermann RE. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24:89-98; PMID:20199124; http://dx.doi.org/10.2165/11530960-000000000-00000
4. Demarest SJ, Hariharan K, Dong J. Emerging antibody combinations in oncology. MAbs 2011; 3:338-51; PMID:21697653; http://dx.doi.org/10.4161/mabs.3. 4.16615
5. Carter P. Improving the efficacy of antibodybased cancer therapies. Nat Rev Cancer 2001; 1:118-29; PMID:11905803; http://dx.doi. org/10.1038/35101072
6. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/mabs. 2.2.11221
7. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1:539-47; PMID:20073127; http://dx.doi. org/10.4161/mabs.1.6.10015
8. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
9. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc. M110.117382
10. Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
11. Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 2009; 28:147-76; PMID:18720354; http://dx.doi.org/10.1002/mas.20190
12. Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:379-94; PMID:20458189; http://dx.doi.org/10.4161. mabs.2.4.11986
13. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov 2012; 11:527-40; PMID:22743980; http://dx.doi.org/10.1038/nrd3746
14. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791
15. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi. org/10.1074/jbc.M110.113910
16. Xie H, Gilar M, Gebler JC. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Anal Chem 2009; 81:5699-708; PMID:19518054; http://dx.doi. org/10.1021/ac900468j
17. Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem 2007; 360:75-83; PMID:17113563; http://dx.doi.org/10.1016/ j. ab.2006.10.012
18. Silva JC, Gorenstein MV, Li GZ, Vissers JPC, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006; 5:144-56; PMID:16219938; http://dx.doi.org/10.1074/mcp. M500230-MCP200
19. Doneanu CE, Xenopoulos A, Fadgen K, Murphy J, Skilton SJ, Prentice H, et al. Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs 2012; 4:24-44; PMID:22327428; http://dx.doi.org/10.4161/mabs.4.1.18748
20. Deperalta G, Alvarez M, Bechtel C, Dong K, McDonald R, Ling V. Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting. MAbs 2013; 5:86-101; PMID:23247543; http://dx.doi.org/10.4161/ mabs.22964
21. Dick LW Jr., Qiu D, Mahon D, Adamo M, Cheng KC. C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol Bioeng 2008; 100:1132-43; PMID:18553400; http://dx.doi.org/10.1002/bit.21855